Assessing venous congestion in critical illness: advantages of the inferior vena cava shape change index over diameter

评估危重症患者的静脉淤血:下腔静脉形状变化指数优于直径测量的优势

阅读:1

Abstract

BACKGROUND: The traditional Venous Excess Ultrasound (VExUS) scoring system relies on inferior vena cava (IVC) diameter measurements, which are affected by multiple confounding factors. The Shape Change Index (SCI) of IVC, defined as the ratio of short-axis diameter to long-axis diameter, may provide a more stable morphological indicator of venous filling. METHODS: In this prospective study, trained operators performed bedside ultrasonography to measure IVC diameter and calculate the SCI of IVC (short-axis diameter/long-axis diameter). Hepatic, portal, and renal venous Doppler waveforms were used to grade venous congestion (Grade 0-3). Diagnostic performance of SCI and IVC diameter for detecting venous congestion was evaluated using receiver operating characteristic(ROC) analysis, with additional exploratory analyses performed to further characterize incremental diagnostic value. RESULTS: A total of 116 venous Doppler examinations from 84 critically ill adults were analyzed. The SCI of IVC demonstrated a stronger correlation with venous congestion grade than IVC diameter (Spearman's ρ = 0.691 vs 0.490, both p < 0.001). For detecting any venous congestion (VExUS Grade ≥1 vs Grade 0), the SCI of IVC showed significantly better diagnostic discrimination than IVC diameter, with an area under the curve of 0.864 compared with 0.767, respectively (p = 0.044). The diagnostic advantage of SCI appeared to be more evident in examinations without advanced venous congestion. Higher SCI values were associated with greater disease severity. CONCLUSIONS: The SCI of IVC demonstrates superior diagnostic performance compared with IVC diameter for the identification of venous congestion in critically ill patients, particularly at earlier or less advanced stages. These findings support the use of SCI as a complementary screening tool within the existing VExUS framework. Further multicenter studies are required to confirm its clinical utility and generalizability.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。